213 related articles for article (PubMed ID: 32702212)
1. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.
Brunner HI; Chen C; Bovis F; De Benedetti F; Espada G; Joos R; Akikusa J; Chaitow J; Boteanu AL; Kimura Y; Rietschel C; Siri D; Smolewska E; Schmeling H; Brown DE; Martini A; Lovell DJ; Huang B; Ruperto N;
Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1264-1274. PubMed ID: 32702212
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
4. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
[TBL] [Abstract][Full Text] [Related]
7. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
8. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
Bharucha KN; Brunner HI; Calvo Penadés I; Nikishina I; Rubio-Pérez N; Oliveira S; Kobusinska K; Schmeling H; Sztajnbok F; Weller-Heinemann F; Zholobova E; Zulian F; Allen R; Chaitow J; Frane J; Wells C; Ruperto N; De Benedetti F;
J Rheumatol; 2018 Aug; 45(8):1173-1179. PubMed ID: 29961686
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Health Status from Early Disease to Adulthood and Associated Prognostic Factors in Juvenile Idiopathic Arthritis.
Tollisen A; Selvaag AM; Aasland A; Lerdal A; Flatø B
J Rheumatol; 2019 Oct; 46(10):1335-1344. PubMed ID: 30877211
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials.
Malattia C; Ruperto N; Pederzoli S; Palmisani E; Pistorio A; Wouters C; Dolezalova P; Flato B; Garay S; Giancane G; Wells C; Douglass W; Brunner HI; De Benedetti F; Ravelli A;
Arthritis Res Ther; 2020 Sep; 22(1):211. PubMed ID: 32912276
[TBL] [Abstract][Full Text] [Related]
14. The Swiss German and Swiss French versions of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).
Hofer M; Ruperto N; Saurenmann R; Sauvain MJ; Huppertz HI; Landgraf JM; Prieur AM;
Clin Exp Rheumatol; 2001; 19(4 Suppl 23):S151-7. PubMed ID: 11510321
[TBL] [Abstract][Full Text] [Related]
15. The Austrian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).
Huemer C; Ruperto N; Huemer M; Sailer-Hoeck M; Kaulfersch W; Schwarz R; Rettenbacher A; Kenzian H; Artacker G; Pilz I; Bernecker M; Huppertz HI; Landgraf JM;
Clin Exp Rheumatol; 2001; 19(4 Suppl 23):S15-9. PubMed ID: 11510320
[TBL] [Abstract][Full Text] [Related]
16. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.
Ruperto N; Lovell DJ; Li T; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Alcala JO; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace C; Alessio M; Quartier P; Cortis E; Eberhard A; Simonini G; Lemelle I; Chalom EC; Sigal LH; Block A; Covucci A; Nys M; Martini A; Giannini EH; ;
Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1542-51. PubMed ID: 20597110
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
Herlin T
Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
[TBL] [Abstract][Full Text] [Related]
19. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ).
Machado CS; Ruperto N; Silva CH; Ferriani VP; Roscoe I; Campos LM; Oliveira SK; Kiss MH; Bica BE; Sztajnbok F; Len CA; Melo-Gomes JA;
Clin Exp Rheumatol; 2001; 19(4 Suppl 23):S25-9. PubMed ID: 11510326
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
